Adjusting the base-case rate of FFDM + DBT follow-up services of 10% across a range encompassing 8%12%% has an appreciable impact on the analysis results.
Data related to reductions in IPD observed after routine pediatric use of 7-valent pneumococcal conjugate vaccine (PCV7) were applied to the modeled base-case rates of disease to generate projected disease-incidence rates after routine pediatric use of PCV13 [ 17].
We found that when the base case rates were multiplied by a factor of approximately eighteen or more, preventive therapy led to a net loss of QALYs; preventive therapy yields QALYs at a cost of less than $50 000 per QALY provided the hepatitis rates are no greater than approximately fifteen times the values we assumed in the base case.
The base case incidence rate of AOM was reduced by - 50% in 0 5 and 5 9 age group down to 16,500 and 10,095 per 100,000 person respectively.
For the base case (a discount rate of 3.9percentt), our estimates indicate that the net impact of the CPPD-VR program (the ENB for the treatment group less the ENB for the comparison group) for women equals $4,538 per client.
Compared to the base-case return rate of 0.74, implementing the routine childhood immunisation programme using TIV instead of LAIV was associated with a lowered return rate per euro invested (0.63).
However, the base case predicts rates in the treated population of both physician visits (3%) and emergency visits (0.4%) which are lower than those predicted using Dormann's study (5%and0.7%7% respectively), the original model (12% and 2% respectively) and close to the lower end of rates reported in the literature (3.5% and 0.9% respectively: see Table 2).
This is because of the small and similar switch rates in clinical/CD4/viral load and clinical/CD4 arms and the larger base case value of regimen switch rates in the clinical arm.
In the base case, a device failure rate of 0%% was assumed.
The base case of the model uses reimbursement rates from the US Medicare fee schedule, presented in 2013 dollars and the model takes a third-party payer perspective as it estimates costs over a 5-year period.
